In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Related Pages

Featured Clinical Trials Supported by the National Cancer Institute

Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.

To find other cancer trials open to enrollment:

  • Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
  • Use the clinical trials search form to look online for trials listed on NCI's website. The form has a Help link for tips about searching for clinical trials.
  • For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
Targeted Therapy for Ovarian Cancer
(Posted: 10/31/2006, Updated: 01/06/2010) - In this trial, women who have undergone initial surgery for ovarian cancer or primary peritoneal cancer will receive standard intravenous chemotherapy and some will receive additional treatment with bevacizumab.

Defining Optimal Therapy for Metastatic and Recurrent Cervical Cancer
(Posted: 12/15/2009) - In this phase III trial, women with metastatic, recurrent, or persistent cervical cancer that cannot be treated with surgery and/or radiation therapy will be randomly assigned to one of four treatment groups: paclitaxel plus cisplatin, paclitaxel plus topotecan, or either of these combinations with the addition of bevacizumab.

Combination Therapy for Patients with Myelodysplastic Syndromes
(Posted: 11/17/2009) - In this trial, patients with myelodysplatic syndrome and symptomatic anemia who have a low or intermediate-1 risk of progression to leukemia will be treated with lenalidomide, and some will randomly assigned to receive epoetin alfa (Procrit).

Combining Chemotherapy and a PARP Inhibitor for Advanced Solid Tumors
(Posted: 11/03/2009) - In this clinical trial, patients who have solid tumors that cannot be removed by surgery or that have spread to other areas of the body will be treated with the PARP inhibitor AZD2281 and chemotherapy drugs cisplatin and gemcitabine.

Testing Satraplatin in Advanced Prostate Cancer
(Posted: 10/20/2009) - In this clinical trial, men with androgen-independent metastatic prostate cancer that has progressed after first-line chemotherapy will be treated with satraplatin and prednisone.

< Previous  6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26  Next >